WuXi XDC Celebrated as the Best CDMO and CRO in the Industry for Consecutive Years

WuXi XDC: Leading the Way in Bioconjugate Development

In the competitive landscape of bioconjugate research and manufacturing, WuXi XDC Cayman Inc. has recently made headlines by securing the titles of 'Best CDMO' (Contract Development and Manufacturing Organization) for the fourth consecutive year and 'Best CRO' (Contract Research Organization) for the second consecutive year at the prestigious 2026 World ADC Awards. This notable achievement places WuXi XDC as the only organization to clinch both awards for two consecutive years, validating its significant contributions to the bioconjugate segment of the pharmaceutical industry.

A Testament to Excellence

The accolades were announced during the 2026 World ADC Conference, an influential event that gathers industry experts and thought leaders to discuss advancements in Antibody-Drug Conjugates (ADCs) and the challenges faced throughout their lifecycle, from research and development to commercialization. Dr. Jimmy Li, the CEO of WuXi XDC, expressed his pride regarding the honors, underscoring the importance of client trust and support in achieving such commendations. He stated, "With the growing demand for bioconjugates, we are committed to technological innovation and delivering value to our clients while pushing the boundaries of what is possible in bioconjugate development."

Industry Leadership and Innovation

Established as a front-runner in the CRDMO sector, WuXi XDC is distinguished by its comprehensive and seamless approach in providing end-to-end services. Their commitment to innovative R&D capabilities has garnered the trust of more than 800 clients, including 15 of the top 20 pharmaceutical companies by revenue. The company has facilitated over 160 Investigational New Drug (IND) applications and maintained a record of enabling 328 iCMC projects as of June 2026, with 51 projects initiated in the first half of the year alone.

The firm's state-of-the-art integrated services have allowed clients to transition from DNA insights to preclinical candidates in a mere 10 months, from it to IND applications in 15 months, and from late-stage development to BLA (Biologics License Application) in 24 to 36 months. This rapid progression underscores WuXi XDC's efficiency and capability to drive complex projects forward.

Advanced Technology Portfolio

WuXi XDC’s proprietary suite of bioconjugation technologies, including WuXiDARx™, WuXiTecan-2™, X-LinC™, and WuXiLinker™, has positioned them at the forefront of the bioconjugate field. Notably, in 2026, two significant licensing agreements were signed based on the WuXiTecan-2™ platform, partnering with Earendil Labs and Ona Therapeutics to advance innovative projects further. Moreover, with research encompassing over 22,000 ADC/XDC molecules, WuXi XDC is pioneering new avenues in bispecific ADCs and dual-payload ADCs, solidifying its reputation for inventive work in the field.

Global Expansion

The company boasts a robust global presence with locations across China and new operations in Singapore, marking a significant milestone with the successful GMP (Good Manufacturing Practice) release of its Singapore production facilities in August 2026. This expansion not only enhances its operational strength but also exemplifies its commitment to meeting the growing global demand for bioconjugates.

With a workforce exceeding 3,600 employees, WuXi XDC prioritizes talent development, emphasizing higher education by employing over 50% of its staff with master's degrees or above. This strategy aligns with the company’s goal of cultivating a global talent pool equipped to face the industry's challenges and drive future advancements.

For more insights into WuXi XDC and its innovative projects, please visit their official website at www.wuxixdc.com.